학술논문
SAR439859, a novel selective estrogen receptor degrader (SERD), demonstrates effective and broad antitumor activity in wild-type and mutant er-positive breast cancer models
Document Type
Article
Author
Shomali, M.; Cheng, J.; Sun, F.; Koundinya, M.; Guo, Z.; Hebert, A.T.; McManus, J.; Levit, M.N.; Hoffmann, D.; Cao, H.; Pollard, J.; Lee, J.S.; Cheng, H.; Bouaboula, M.; Courjaud, A.; Arrebola, R.; Besret, L.; Caron, A.; Abecassis, P.-Y.; Schio, L.; El-Ahmad, Y.; Halley, F.; Tabart, M.; Certal, V.; Thompson, F.; McCort, G.; Filoche-Romme, B.; Garcia-Echeverria, C.; Debussche, L.; Bangari, D.S.
Source
In: Molecular Cancer Therapeutics . (Molecular Cancer Therapeutics, 1 February 2021, 20(2):250-262)
Subject
Language
English
ISSN
15388514
15357163
15357163